XILIO THERAPEUTICS INC (XLO) Institutional Shareholders
XILIO THERAPEUTICS INC (XLO) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026. The institutional investors covered on this page collectively reported approximately $32.68M in XLO holdings during the latest filing period.
Bain Capital Life Sciences Investors, Llc is currently the largest disclosed institutional shareholder of XLO tracked by InsiderSet, reporting ownership valued at approximately $6.36M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $5.92M, representing an estimated loss of -6.99% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 93% of the total disclosed XLO value among the investors covered in this analysis. Major shareholders include Bain Capital Life Sciences Investors, Llc, Gilead Sciences, Inc., Orbimed Advisors Llc, and several other long-term asset managers with concentrated positions in XILIO THERAPEUTICS INC (XLO).
This page ranks the largest institutional XLO shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
Institutional Holders
28
Total Reported Value
$32.68M
Largest Holder
Bain Capital Life Sciences Investors, Llc
Largest Position
$6.36M
Insider Transactions (90d)
0
Latest Filing Quarter
Q2 2026
New Institutional Positions
49
Funds Exiting Positions
0
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 0.38% | 664,021 | $6,361,322 | $5,916,427 | -$444,895 | -6.99% | |
| Gilead Sciences, Inc. | 0.38% | 650,389 | $6,230,727 | $5,794,966 | -$435,761 | -6.99% | |
| Orbimed Advisors Llc | 0.11% | 592,300 | $5,674,234 | $5,277,393 | -$396,841 | -6.99% | |
| Frazier Life Sciences Management, L.P. | 0.09% | 422,505 | $4,047,598 | $3,764,520 | -$283,078 | -6.99% | |
| Stonepine Capital Management, Llc | 1.65% | 225,994 | $2,165,023 | $2,013,607 | -$151,416 | -6.99% | |
| Vanguard Capital Management Llc | 0.00% | 178,517 | $1,710,193 | $1,590,586 | -$119,607 | -6.99% | |
| Sio Capital Management, Llc | 0.25% | 152,464 | $1,460,605 | $1,358,454 | -$102,151 | -6.99% | |
| Adage Capital Partners Gp, L.L.C. | 0.00% | 111,541 | $1,068,563 | $993,830 | -$74,733 | -6.99% | |
| Merck & Co., Inc. | 0.19% | 105,982 | $1,015,308 | $944,300 | -$71,008 | -6.99% | |
| Renaissance Technologies LLC | Jim Simons | 0.00% | 64,153 | $614,586 | $571,603 | -$42,983 | -6.99% |
| Morgan Stanley | 0.00% | 56,954 | $545,619 | $507,460 | -$38,159 | -6.99% | |
| Geode Capital Management, Llc | 0.00% | 39,055 | $374,174 | $347,980 | -$26,194 | -7.00% | |
| Citadel Advisors Llc | 0.00% | 25,950 | $248,601 | $231,215 | -$17,387 | -6.99% | |
| Vanguard Fiduciary Trust Co | 0.00% | 22,594 | $216,451 | $201,313 | -$15,138 | -6.99% | |
| Bridgeway Capital Management, Llc | 0.00% | 17,544 | $168,072 | $156,317 | -$11,755 | -6.99% | |
| Two Sigma Investments, Lp | 0.00% | 14,544 | $139,332 | $129,587 | -$9,745 | -6.99% | |
| Velan Capital Investment Management Lp | 0.08% | 14,285 | $136,850 | $127,279 | -$9,571 | -6.99% | |
| Gsa Capital Partners Llp | 0.01% | 13,590 | $130,000 | $121,087 | -$8,913 | -6.86% | |
| State Street Corp | 0.00% | 13,311 | $127,519 | $118,601 | -$8,918 | -6.99% | |
| Prelude Capital Management, Llc | 0.01% | 11,600 | $111,128 | $103,356 | -$7,772 | -6.99% | |
| Blackrock, Inc. | 0.00% | 8,757 | $83,892 | $78,025 | -$5,867 | -6.99% | |
| Cwm, Llc | 0.00% | 4,206 | $35,372 | $37,475 | +$2,103 | +5.95% | |
| Steward Partners Investment Advisory, Llc | 0.00% | 714 | $6,840 | $6,362 | -$478 | -6.99% | |
| Security National Bank Of Sioux City Iowa | 0.00% | 321 | $3,075 | $2,860 | -$215 | -6.99% | |
| Barclays Plc | 0.00% | 115 | $1,102 | $1,025 | -$77 | -7.02% | |
| Key Financial Inc | 0.00% | 59 | $565 | $526 | -$39 | -6.96% | |
| Jones Financial Companies Lllp | 0.00% | 29 | $262 | $258 | -$4 | -1.38% | |
| Ubs Group Ag | 0.00% | 14 | $134 | $125 | -$9 | -6.91% |
Frequently asked questions about XLO
Who are the largest institutional holders of XLO?
The largest institutional holders of XLO reported in the latest SEC Form 13F filings include Bain Capital Life Sciences Investors, Llc, Gilead Sciences, Inc., Orbimed Advisors Llc, Frazier Life Sciences Management, L.P., and Stonepine Capital Management, Llc. InsiderSet ranks institutional holders by their latest reported XLO position.
What is XLO institutional ownership?
This page tracks XLO positions reported by institutional investment managers through SEC Form 13F. XILIO THERAPEUTICS INC (XLO) institutional ownership on InsiderSet reflects disclosed 13F holdings among the managers we analyze, not every shareholder of the stock.
How many institutions own XLO?
InsiderSet currently tracks 28 institutional managers reporting XLO holdings in the latest available 13F data. This count reflects institutions included in the SEC Form 13F filings analyzed by InsiderSet and should not be interpreted as the total number of XLO shareholders.
How much XLO stock do institutions own?
Institutional investment managers disclosed approximately $32.68M in XLO holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value.
When was XLO institutional ownership last updated?
The latest XLO institutional ownership data on InsiderSet is based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time institutional holdings.
Are institutional XLO holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by institutional investment managers as of the end of the reporting quarter. An institution may have changed its XLO position after the reporting date.
Are institutions buying or selling XLO?
Institutional buying and selling can be analyzed by comparing XLO positions across consecutive 13F reporting periods. InsiderSet's XLO Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View XLO ownership changes.
How has XLO institutional ownership changed over time?
InsiderSet tracks XLO institutional holdings across multiple 13F reporting periods, allowing investors to compare institutional holder counts, reported value, and reported shares over time.